Stocktoria
Barinthus Biotherapeutics plc. BRNS
Barinthus Biotherapeutics plc. financials (annual)
Bars are annual figures from 2020 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | $0 | $15.0M | $802,000 | $44.7M | $268,000 | $4.8M |
| R&D expense | $25.6M | $42.2M | $44.9M | $42.4M | $20.4M | $14.4M |
| Operating income | -$70.6M | -$68.0M | -$83.9M | -$4.0M | -$45.2M | -$20.0M |
| Interest expense | — | — | $28,000 | $19,000 | $2.7M | $3.6M |
| Income tax | -$175,000 | -$44,000 | -$3.1M | -$4.5M | -$28,000 | $95,000 |
| Net income | -$66.4M | -$61.1M | -$73.3M | $5.3M | -$50.9M | -$17.7M |
| EPS (diluted) | $-1.64 | $-1.55 | $-1.91 | $0.14 | $-1.96 | $-2.24 |
| Operating cash flow | -$48.0M | -$28.9M | -$50.9M | -$14.4M | -$32.6M | -$11.0M |
| Free cash flow | -$48.0M | -$29.8M | -$56.3M | -$20.6M | -$33.7M | -$11.3M |
| Cash & equivalents | $70.5M | $110.7M | $142.1M | $194.4M | $214.1M | $43.3M |
| Total assets | $98.2M | $160.3M | $214.5M | $270.2M | $280.7M | $50.7M |
| Total liabilities | $23.9M | $30.2M | $27.5M | $27.0M | $28.2M | $53.8M |
| Shareholders' equity | $74.3M | $130.1M | $187.0M | $243.2M | $252.6M | -$36.9M |
Growth · year-over-year
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue growth | -100.0% | +1766.5% | -98.2% | +16580.2% | -94.4% | — |
| Net income growth | — | — | -1473.0% | — | — | — |
| EPS growth | — | — | -1464.3% | — | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.